Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Michael Becich
AddedMar 31, 2024
UpdatedMay 31, 2026
Michael Becich

Michael Becich

Co-Founder, SpIntellx

CrunchbaseLinkedIn

Michael Becich's Career

SpIntellx
SpIntellx

Pittsburgh, PA, US

Co-Founder
PredxBio
PredxBio

Pittsburgh, PA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Michael Becich's Career

SpIntellx
SpIntellx
Seed$1.7M52017Pittsburgh, PA, US
Co-Founder

Leadership at SpIntellx

Dusty Majumdar, PhDDusty Majumdar, PhDCEO
Jeffrey L FineJeffrey L FineCo-Founder
S. Chakra ChennubhotlaS. Chakra ChennubhotlaCo-Founder
D. Lansing TaylorD. Lansing TaylorCo-Founder

Similar to SpIntellx

PredxBioPredxBioPittsburgh, PA, USDiagnostics, Precision Pathologyest. 2017PredxBioPittsburgh, PA, US · est. 2017

PredxBio: Advancing precision pathology with AI for optimized clinical trials and personalized therapy.

Seed · $1.1M13
IntelligenciaIntelligenciaTel Aviv, Tel Aviv District, ILData Analyticsest. 2017IntelligenciaTel Aviv, Tel Aviv District, IL · est. 2017

Intelligencia: Pioneering Machine Learning algorithms to optimize and de-risk clinical development.

Series A · $15.5M150
IntioIntioBroomfield, CO, USMedical Softwareest. 2005IntioBroomfield, CO, US · est. 2005

INTIO: Specialized software developer for comprehensive interventional oncology therapies.

Pre-Seed · $12.7M30
Singularity.AISingularity.AISan Jose, CA, USPathologyest. 2018Singularity.AISan Jose, CA, US · est. 2018

AI-powered platform accelerating medical innovation through secure, interactive data analysis.

Series A · $5M30
PredxBio
PredxBio
Seed$1.1M132017Pittsburgh, PA, US
Co-Founder

Leadership at PredxBio

Chakra ChennubhotlaChakra ChennubhotlaCo-Founder

Similar to PredxBio

SpIntellxSpIntellxPittsburgh, PA, USAnalytics, Softwareest. 2017SpIntellxPittsburgh, PA, US · est. 2017

SpIntellx develops AI-powered software for personalized medicine, using spatial analytics on pathology samples.

Seed · $1.7M5
BioAI HealthBioAI HealthGoffstown, NH, USAI Diagnostics, Biotechest. 2020BioAI HealthGoffstown, NH, US · est. 2020

BioAI Health: Leveraging AI for improved disease diagnosis, therapy response prediction, and clinical trials.

Seed · $3M9
Path BioAnalyticsPath BioAnalyticsChapel Hill, NC, USDrug Developmentest. 2014Path BioAnalyticsChapel Hill, NC, US · est. 2014

PBA, a US-based company, pioneers in precision medicine, developing and tailoring treatments for specific patient groups.

Pre-Seed · $100k2
HI-BioHI-BioSan Francisco, CA, USBiotechest. 2021HI-BioSan Francisco, CA, US · est. 2021

HI-Bio pioneers precision medicine, targeting cellular drivers to treat immune-mediated diseases.

Series B · $215M48

Michael Becich's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Michael Becich

Tom RichardsTom RichardsBoard Member · CDWDario VignaliDario VignaliCo-Founder · Tizona TherapeuticsAlexandra HidalgoAlexandra HidalgoBoard Member · University of PittsburghAnthony DelittoAnthony DelittoBoard Member · University of PittsburghMargaret HsiehMargaret HsiehBoard Member · University of PittsburghRon StallRon StallBoard Member · University of Pittsburgh